India Veterinary Parasiticides Market Size, Share, Growth, and Industry Analysis, By Product Type (EndoparasiticidesAnthelminticsAntiprotozoals, EctoparasiticidesInsecticidesAcaricides, EndectocidesMacrocyclic lactones (e.g., ivermectin, moxidectin)Isoxazolines), By Animal Type (Companion AnimalsDogsCatsOthers (birds, rabbits, etc.), Livestock AnimalsCattleSheep and GoatsPoultrySwineOthers (horses, camels, etc.)) and Forecast, 2026-2034

India Veterinary Parasiticides Market Trends

Shift Toward Broad-Spectrum, Convenient Parasite Protection

Product development is shifting toward broad-spectrum formulations combining protection against multiple parasite classes with monthly dosing. Modern formulations can combine 3 or 4 active ingredients and target fleas, ticks, heartworms, roundworms, hookworms and tapeworms through a single regimen. Boehringer Ingelheim's NexGard PLUS, for example, uses 3 active ingredients and is administered monthly, illustrating the technology direction toward simplified compliance.

India's underlying animal base—536.76 million livestock and 851.81 million poultry in the latest nationwide census—supports high-volume parasite-control requirements.

Challenges in India Veterinary Parasiticides Market

Large Treatment Base Raises Execution and Coverage Complexity

Serving more than 536 million livestock and 851 million poultry requires extensive last-mile distribution, veterinarian engagement and farmer education. Simultaneously, estimated pet dogs increased by about 57% from 21.42 million in 2019 to 33.61 million in 2023.

India Veterinary Parasiticides Market Segmentation

The industry is segmented by product type, animal type, mode of administration, distribution channel and end-user. Supplied 2026 data indicate endoparasiticides account for approximately 45.17% of product revenue, while companion animals represent approximately 55.50% of animal-type revenue.

By Product Type

Endoparasiticides—including anthelmintics and antiprotozoals—are the largest category at USD 313.13 million in 2026 and are forecast to reach USD 483.11 million by 2034, recording 5.57% CAGR. Their 2026 contribution is approximately 45.17%, compared with 30.24% for ectoparasiticides and 24.59% for endectocides.

Endoparasiticides are also the fastest-growing supplied product category at 5.57% CAGR. Ectoparasiticides, including insecticides and acaricides, rise from USD 209.65 million to USD 313.54 million at 5.16%, while endectocides, including macrocyclic lactones and isoxazolines, increase from USD 170.46 million to USD 256.30 million at 5.23%.

By Animal Type

Companion animals—dogs, cats and other pets—lead with USD 384.55 million in 2026 and USD 579.95 million by 2034, representing 55.50% of the supplied 2026 animal-type total and recording 5.27% CAGR. Livestock animals account for USD 308.39 million in 2026.

Livestock animals, encompassing cattle, sheep and goats, poultry, swine and others, are the faster-growing category at 5.37% CAGR and reach USD 468.63 million by 2034. Their approximately 44.50% contribution in 2026 reflects India's substantial production-animal base.

By Mode of Administration

Oral products include tablets, chewables and liquids; topical formulations comprise spot-ons, sprays and pour-ons, alongside injectable and other formats. Monthly oral combinations increasingly integrate 3 active ingredients and multi-parasite coverage, while topical products can provide approximately 30 days of protection. Quantified segment revenue/CAGR was not supplied for this classification and is therefore not fabricated.

By Distribution Channel

Veterinary clinics/hospitals, retail pharmacies, online pharmacies, and feed stores/cooperatives form the principal channels. The underlying addressable base includes 536.76 million livestock and an estimated 43.90 million pet dogs in 2026. No channel-level revenue or CAGR was supplied.

By End-User

Veterinarians, pet owners, farmers/livestock owners and animal-welfare organizations constitute key end-users. Pet dogs alone are estimated to increase from 33.61 million in 2023 to 51.53 million in 2028, while livestock exceeds 536 million animals.

India Veterinary Parasiticides Market Outlook

North, South, East, West and Central India collectively form the national opportunity, supported by India's 536.76 million livestock and 851.81 million poultry. The supplied mandatory tables provide only national values—USD 693.24 million in 2026 and USD 1,052.95 million in 2034—and do not provide defensible regional percentage shares; therefore regional shares are not fabricated. State-level livestock concentration, urban pet ownership, veterinary infrastructure and livestock-versus-companion-animal mix remain the primary geographic differentiators.

Top players in India Veterinary Parasiticides Market

• Boehringer Ingelheim
• Zoetis
• MSD Animal Health
• Elanco Animal Health
• Virbac
• Intas Animal Health
• Hester Biosciences
• Zenex Animal Health
• Ashish Life Science
• Venkateshwara Hatcheries
• Inmed Animal Health
• Vetnation Pharma

Top Two Companies

• Boehringer Ingelheim

The company-specific India revenue percentage is not publicly established in the reviewed sources and is therefore not estimated. The company has a strong parasite-control position spanning canine and feline portfolios, including NexGard-family and FRONTLINE products globally. In August 2024, its India operation entered a distribution partnership with Vvaan Lifesciences specifically for the pet parasiticide portfolio, supporting wider domestic reach.

• MSD Animal Health

A reliable India-specific percentage share is likewise not publicly disclosed in the reviewed evidence. MSD maintains established veterinary operations in India and markets parasite-control products including Butox, positioned by the company as an ectoparasiticide, alongside broader companion- and production-animal healthcare portfolios. The breadth of veterinary relationships and livestock presence supports competitive positioning across institutional and practitioner-led channels.

Recent Developments in India Veterinary Parasiticides Market

• 2025: JK Paper acquired Quadragen VetHealth, marking diversification into veterinary healthcare and increasing corporate activity in India's animal-health ecosystem.

Research Methodology

The analysis uses 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast period, with 2022–2024 treated as historical years. Mandatory supplied market figures were retained without alteration: the product-type total progresses from USD 657.96 million in 2025 to USD 693.24 million in 2026 and USD 1,052.95 million in 2034 at 5.32% CAGR. Segment percentages were calculated directly from supplied values. Secondary validation incorporates government livestock statistics, corporate disclosures and publicly available industry information. Where regional, administration, distribution-channel, end-user or company-share numerical data were not supplied or reliably disclosed, percentages were not invented.